Carepen vet Spenalyf, dreifa 600 mg Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

carepen vet spenalyf, dreifa 600 mg

vetcare ltd.* - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg

Streptocillin vet. Stungulyf, dreifa Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

streptocillin vet. stungulyf, dreifa

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Depomycine, vet. Stungulyf, dreifa Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

depomycine, vet. stungulyf, dreifa

intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Geepenil Vet. Stungulyfsstofn og leysir, lausn 24 g Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

geepenil vet. stungulyfsstofn og leysir, lausn 24 g

orion corporation - benzylpenicillinum natríum - stungulyfsstofn og leysir, lausn - 24 g

Penovet vet. Stungulyf, dreifa 300 .000 a.e./ml Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

penovet vet. stungulyf, dreifa 300 .000 a.e./ml

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml

Procapen vet Spenalyf, dreifa 3 g Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

procapen vet spenalyf, dreifa 3 g

animedica gmbh* - benzylpenicillinprocainum - spenalyf, dreifa - 3 g

Benestermycin vet. Spenalyf, smyrsli Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

benestermycin vet. spenalyf, smyrsli

boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli

Penethaone vet (Penethamate) Stungulyfsstofn og leysir, dreifa 236,3 mg/ml Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

penethaone vet (penethamate) stungulyfsstofn og leysir, dreifa 236,3 mg/ml

divasa-farmavic s.a. - penethamate hydriodide - stungulyfsstofn og leysir, dreifa - 236,3 mg/ml

Tibsovo Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.